Deck 3: General Pharmacokinetic and Pharmacodynamic Principles
سؤال
سؤال
سؤال
سؤال
سؤال
سؤال
سؤال
سؤال
سؤال
سؤال
سؤال
فتح الحزمة
قم بالتسجيل لفتح البطاقات في هذه المجموعة!
Unlock Deck
Unlock Deck
1/11
العب
ملء الشاشة (f)
Deck 3: General Pharmacokinetic and Pharmacodynamic Principles
1
The primary care NP should understand that a drug is at a therapeutic level when it is:
A) at peak plasma level.
B) past 4 or 5 half-lives.
C) at its steady plasma state.
D) between minimal effective concentration and toxic levels.
A) at peak plasma level.
B) past 4 or 5 half-lives.
C) at its steady plasma state.
D) between minimal effective concentration and toxic levels.
between minimal effective concentration and toxic levels.
2
A patient wants to know why a cheaper version of a drug cannot be used when the primary care NP writes a prescription for a specific brand name of the drug and writes,"Dispense as Written." The NP should explain that a different brand of this drug:
A) may cause different adverse effects.
B) does not necessarily have the same therapeutic effect.
C) is likely to be less safe than the brand specified in the prescription.
D) may vary in the amount of drug that reaches the site of action in the body.
A) may cause different adverse effects.
B) does not necessarily have the same therapeutic effect.
C) is likely to be less safe than the brand specified in the prescription.
D) may vary in the amount of drug that reaches the site of action in the body.
may vary in the amount of drug that reaches the site of action in the body.
3
A primary care NP is preparing to prescribe a drug and notes that the drug has nonlinear kinetics.The NP should:
A) monitor frequently for desired and adverse effects.
B) administer a much higher initial dose as a loading dose.
C) monitor creatinine clearance at baseline and periodically.
D) administer the drug via a route that avoids the first-pass effect.
A) monitor frequently for desired and adverse effects.
B) administer a much higher initial dose as a loading dose.
C) monitor creatinine clearance at baseline and periodically.
D) administer the drug via a route that avoids the first-pass effect.
monitor frequently for desired and adverse effects.
4
A patient asks the primary care NP which medication to use for mild to moderate pain.The NP should recommend:
A) APAP.
B) Tylenol.
C) acetaminophen.
D) any over-the-counter pain product.
A) APAP.
B) Tylenol.
C) acetaminophen.
D) any over-the-counter pain product.
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 11 في هذه المجموعة.
فتح الحزمة
k this deck
5
A primary care NP is prescribing a drug for a patient who does not take any other medications.The NP should realize that:
A) CYP450 enzyme reactions will not interfere with this drug's metabolism.
B) substrates such as alcohol cannot interfere with the drug when the patient is abstaining.
C) food-drug interactions are limited to those where food enhances or inhibits drug absorption.
D) a thorough history of diet, alcohol use, smoking, and over-the-counter and herbal products is required.
A) CYP450 enzyme reactions will not interfere with this drug's metabolism.
B) substrates such as alcohol cannot interfere with the drug when the patient is abstaining.
C) food-drug interactions are limited to those where food enhances or inhibits drug absorption.
D) a thorough history of diet, alcohol use, smoking, and over-the-counter and herbal products is required.
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 11 في هذه المجموعة.
فتح الحزمة
k this deck
6
A patient is taking drug A and drug B.The primary care NP notes increased effects of drug B.The NP should suspect that in this case drug A is a cytochrome P450 (CYP450)enzyme:
A) inhibitor.
B) substrate.
C) inducer.
D) metabolizer.
A) inhibitor.
B) substrate.
C) inducer.
D) metabolizer.
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 11 في هذه المجموعة.
فتح الحزمة
k this deck
7
A patient takes an oral medication that causes gastrointestinal upset.The patient asks the primary care NP why the drug information insert cautions against using antacids while taking the drug.The NP should explain that the antacid may:
A) alter drug absorption.
B) alter drug distribution.
C) lead to drug toxicity.
D) increase stomach upset.
A) alter drug absorption.
B) alter drug distribution.
C) lead to drug toxicity.
D) increase stomach upset.
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 11 في هذه المجموعة.
فتح الحزمة
k this deck
8
A patient receives an inhaled corticosteroid to treat asthma.The patient asks the primary care NP why the drug is given by this route instead of orally.The NP should explain that the inhaled form:
A) is absorbed less quickly.
B) has reduced bioavailability.
C) has fewer systemic side effects.
D) provides dosing that is easier to regulate.
A) is absorbed less quickly.
B) has reduced bioavailability.
C) has fewer systemic side effects.
D) provides dosing that is easier to regulate.
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 11 في هذه المجموعة.
فتح الحزمة
k this deck
9
A primary care NP wishes to order a drug that will be effective immediately after administration of the drug.Which route should the NP choose?
A) Rectal
B) Topical
C) Sublingual
D) Intramuscular
A) Rectal
B) Topical
C) Sublingual
D) Intramuscular
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 11 في هذه المجموعة.
فتح الحزمة
k this deck
10
A patient will begin taking two drugs that are both protein-bound.The primary care NP should:
A) prescribe increased doses of both drugs.
B) monitor drug levels, actions, and side effects.
C) teach the patient to increase intake of protein.
D) stagger the doses of drugs to be given 1 hour apart.
A) prescribe increased doses of both drugs.
B) monitor drug levels, actions, and side effects.
C) teach the patient to increase intake of protein.
D) stagger the doses of drugs to be given 1 hour apart.
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 11 في هذه المجموعة.
فتح الحزمة
k this deck
11
A primary care nurse practitioner (NP)prescribes a drug to an 80-year-old African-American woman.When selecting a drug and determining the correct dose,the NP should understand that the knowledge of how age,race,and gender may affect drug excretion is based on an understanding of:
A) bioavailability.
B) pharmacokinetics.
C) pharmacodynamics.
D) anatomy and physiology.
A) bioavailability.
B) pharmacokinetics.
C) pharmacodynamics.
D) anatomy and physiology.
فتح الحزمة
افتح القفل للوصول البطاقات البالغ عددها 11 في هذه المجموعة.
فتح الحزمة
k this deck

